Boehringer Ingelheim

Boehringer Ingelheim

Corporation

Telefax

TO:

R. T. Shiao

DATE:

July 25, 2006

Fax Number:

571-273-0707

Total Number of pages:

21 (including cover sheet)

Re: Supplemental Response - 9/268

Attached as per Anthony Bottino's request.

Regards, Linda Boland-Covey Linda Boland-Covey
Telephone (203) 791-6311
Telefax (203) 798-4408
E-Mail Ibolandc@rdg.boehringeringelheim.com

900 Ridgebury Rd/P.O. Box 368 Ridgefield, CT 06877-0368

THIS COMMUNICATION IS INTENDED ONLY FOR THE PERSON OR ENTITY TO WHOM IT IS ADDRESSED (NAMED ABOVE): THE INFORMATION IT CONTAINS MAY BE CONFIDENTIAL AND/OR LEGALLY PROVILIGED AND PROTECTED IN LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, IT IS HEREBY STIPULATED THAT ANY COPYING, DUPLICATION OR DISTRIBUTION OF THIS DOCUMENT IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR PLEASE TELEPHONE OR FAX US IMMEDIATELY ON THE NUMBERS SHOWN HERE.

9/268

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : COGAN, D., et al) Art Unit: 1626

U.S. Appln. No. : 10/718,380) Examiner: Shiao, R.T.

Confirmation No.: 9526 U.S. Filing Date: 11/20/2003

Title of Invention: Cytokine Inhibitors

Attny. Docket No.: 9/268

Via fax 571-273-8300 Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL RESPONSE

Sir:

In response to the office action dated 2/09/2006, applicants submit herewith a Supplemental Response to the Response dated 06/06/2006, please reconsider the above-identified patent application in view of the following:

Amendments to the claims which are reflected in the Current Listing of Claims which begin on page 2 of this paper.

Remarks/Arguments which begin on page 21 of this paper.